pemetrexed+cisplatin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerSoft Tissue Sarcoma

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Carboplatin Plus Paclitaxel

Bayer

Phase 3

22

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

23

pemetrexed+cisplatin

AstraZeneca

Phase 3

44

HLX17

Shanghai Henlius Biotech

Phase 3

25

Remeron

OOrganon and Co

Preclinical

16

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Treatment

GSK

Preclinical

18

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

2Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Completed·Pfizer·Phase 3·NCT01639001·207 enrolled

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Completed·—·Phase 2·NCT01204307·101 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting·AstraZeneca·Phase 2·NCT05061550·630 enrolled

Show 1 more trial

A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).

Active, not recruiting·AstraZeneca·Phase 3·NCT04035486·587 enrolled

Soft Tissue Sarcoma1 trial

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Recruiting·YYonsei University·Phase 2·NCT04605770·164 enrolled

Cisplatin1 trial

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Unknown status·GGuangzhou Medical University·Phase 2·NCT03374280·178 enrolled

Non-squamous NSCLC1 trial

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

Terminated·SSpanish Lung Cancer Group·Phase 2·NCT01088906·57 enrolled

Malignant Pleural Mesothelioma1 trial

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02639767

2 more indications

Chemotherapy1 trial

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02436733·64 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Active, not recruiting·AstraZeneca·Phase 2·NCT03775486·401 enrolled

Details

Drug Info

Related News